In light of the high recurrence rate of NSCLC after RT, and considering CSC as the target population with high radioresistance, we suggest a combination of radiation and agents that inhibit IL-6 signaling (or its downstream signaling) to reduce CSC-mediated radioresistance in lung cancer. The gene discussed is IL6; the disease is lung carcinoma.